ReviewAbdominal radiology (New York)2025
Research progress in multimodal radiomics of rectal cancer tumors and peritumoral regions in MRI.
Review in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- From signal-intensity ratio to decision-grade triage in prostate MRI.Abdominal radiology (New York) · 2026Article
- MR-based techniques for imaging prostate cancer metabolism: current status and future perspectives.Abdominal radiology (New York) · 2026Review
- MRI-Based Morphological Features as Predictors of Clinical Outcomes in Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy: Insights from a Single-Institution Experience.Journal of clinical medicine · 2026Article
- The Value of MRI-Based Radiomics in Predicting the Pathological Nodal Status of Rectal Cancer: A Systematic Review and Meta-Analysis.Bioengineering (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Rectal cancer (RC) is one of the most common malignant tumors of the digestive system and has an alarmingly high incidence and mortality rate globally. Compared to conventional imaging examinations, radiomics can extract quantitative features that reflect tumor heterogeneity and mine data from medical images. In this review, we discuss the potential value of multimodal MRI-based radiomics in the diagnosis and treatment of RC, with a special emphasis on the role of peritumoral tissue characteristics in clinical decision-making. Existing studies have shown that a radiomics model integrating intratumoral and peritumoral characteristics has good application prospects in RC staging evaluation, efficacy prediction, metastasis monitoring, recurrence early warning, and prognosis judgment. At the same time, this paper also objectively analyzes the existing methodological limitations in this field, including insufficient data standardization, inadequate model validation, limited sample size and poor reproducibility of results. By combining existing evidence, this review aimed to enhance the attention of clinicians and radiologists on the characteristics of peritumoral tissues and promote the translational application of radiomics technology in the individualized treatment of RC.
Indexed as
Identifiers
40448847What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.